The Cambridge and London Technology and Life Sciences team advised Closed Loop Medicine in a global co-development partnership with Pharmanovia, to provide dose optimized personalized therapies. The partnership will initially focus on the development and launch of a drug + software combination version of a first-line anti-hypertensive in the UK, before phased global roll-out and additional therapies are added.
Goodwin previously advised Closed Loop Medicine in its 2021 financing.
Closed Loop Medicine is a leading TechBio company, developing combination prescription drug plus software therapy products that enable personalized dose optimization.
Pharmanovia is a global pharmaceutical company that commercializes novel medicines and revitalizes, extends and expands the lifecycle of established medicines.
The Goodwin team included Tim Worden, Gretchen Scott, James Taylor, Joseph Ndep, and Beth Ashbridge.
For additional details, please read Closed Loop Medicine’s press release.